Cannabidiol in the management of bruxism in behavioral variant of frontotemporal degeneration. Issue 2 (4th March 2021)

• Record Type: Journal Article
• Authors: Pina-Escudero, Stefanie Danielle; Okada de Oliveira, Maira; Snyder, Alisson; Miller, Bruce L.
• Is Part Of: Neurocase. Volume 27:Issue 2(2021)
• Page Start: 209
• Page End: 211
• Publication Date: 2021-03-04
• Subjects: Bruxism -- cannabidiol -- behavioral variant of frontotemporal dementia; Neurology -- Periodicals; Neuropsychology -- Case Report; Mental Disorders -- Case Report; Nervous System Diseases -- Case Report; 616.8
• DOI: 10.1080/13554794.2021.1917620
• Languages: English
• ISSNs: 1355-4794

Abstract

ABSTRACT: Awake bruxism is an understudied feature of behavioral variant of frontotemporal dementia (bvFTD). We present the case of aman who presented with psychiatric, behavioral, cognitive changes, and teeth clenching that resulted in significant changes in his teeth alignment including an underbite. He received multiple treatments with partial response. He then started using acannabidiol (CBD) capsule, and the grinding was almost completely relieved after this intervention. There is still no standardized pharmacology treatment for bruxism in patients with bvFTD. As aconsequence, acase-by-case approach is suggested. CBD can be helpful as an adjunct therapeutic agent for awake bruxism.Not StartedCompletedRejected.